Treatment of parkinsonism with L-dopa (study of 105 patients).
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000856:Anorexia Nervosa / Q000209:etiology; D001219:Aspartate Aminotransferases / Q000097:blood; D001806:Blood Urea Nitrogen; D002648:Child; D002675:Child, Preschool; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007022:Hypotension / Q000209:etiology; D001523:Mental Disorders / Q000209:etiology; D008875:Middle Aged; D009069:Movement Disorders / Q000209:etiology; D009325:Nausea / Q000209:etiology; D010146:Pain / Q000209:etiology; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D013997:Time Factors
D004295:Dihydroxyphenylalanine; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase